Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
Crossref DOI link: https://doi.org/10.1186/s40661-017-0045-x
Published Online: 2017-03-21
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Monk, Bradley J.
Huh, Warner K.
Rosenberg, Julie Ann
Jacobs, Ira
Funding for this research was provided by:
Pfizer (N/A)
